AI in Employment: Navigating the Legal Landscape with Lessons from I, Robot — The Good Bot Podcast
5 Key Takeaways | Artificial Intelligence: What Tax Professionals Need to Know
The FinReg Frontier: AI and Machine Learning in Consumer Finance — The Consumer Finance Podcast
Key Discovery Points: AI Says AI Will Replace Paralegals… But Not So Fast!
AI Discrimination and Emerging Best Practices – Part 2 - The Good Bot Podcast
Podcast - Decoding the Future of AI Regulation and Frontier Models
A Conversation with Alexandra Johnson, CEO/Co-Founder of Rubber Ducky Labs, AI Recommender Systems Pioneer
AI Discrimination and Emerging Best Practices – Part 1 — The Good Bot Podcast
Dan Rudoy Examines the Impact of AI on IP Strategy
Seeing into the Future: Moving Beyond AI to Visual Intelligence with Oculi CEO Charbel Rizk
A Brief Overview of Colorado’s Recently Enacted AI Law
Spotlight on Lightmatter, the Photonic (Super) Computing Company Ready to Power the AI Revolution
Podcast - Part 2: An FTC Official Speaks About the Regulation of AI Technology
A Deep Dive into HUD's New Guidance on AI-Driven Targeted Advertising — The Consumer Finance Podcast
[Webinar] AI and Data Privacy: Minimizing Risk and Maximizing Opportunity
AD Nauseam: AI – We Had to Discuss it Eventually – Part 2
(Podcast) The Briefing: Writers, Actors, AI: The AI Centric Changes to the WGA and SAG Agreements
AI Talk With Juliana Neelbauer: Third-Party Risk Management and Legal Perspective
Business Better Podcast Episode: Cyber Adviser – Financial Services 2024 Privacy and Cybersecurity Preview
DE Under 3: Complaint Dismissed Alleging an Applicant Screening Tool Discriminated Based on Race, Age, & Disability
The U.S. Food and Drug Administration (FDA) recently issued a Warning Letter citing a failure to obtain marketing authorization via a premarket approval (PMA) or 510(k) clearance as well as Good Manufacturing Practice (GMP)...more
Transparency of artificial intelligence (AI) systems in healthcare is quickly becoming a central concern for regulators due to potential impacts on patient safety, healthcare quality, bias mitigation, and public trust. To...more
On April 10, 2025, the U.S. Food and Drug Administration (FDA) announced it will be phasing out the current requirements for animal testing in the development of monoclonal antibody therapies and other drugs, replacing them...more
Artificial intelligence has become one of the most transformative forces in health care, reshaping everything from drug discovery to diagnostics. For pharmaceutical and medical device companies, AI-driven solutions present...more
The rapid advancement of Artificial Intelligence (AI) and Machine Learning (ML) is revolutionizing the healthcare industry. However, as these innovative devices emerge, understanding the complex regulatory landscape becomes...more
n March 15, the U.S. Food and Drug Administration (FDA) published a paper titled “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.” This paper describes the FDA’s strategy for...more